Sucampo Acquires Vtesse Inc.
April 03, 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1) Increases Company Focus on Specialized Diseases with High Unmet Need ...
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 16th Annual Needham Healthcare Conference
March 28, 2017 16:01 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., March 28, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Oppenheimer 27th Annual Healthcare Conference
March 15, 2017 17:01 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., March 15, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...
Sucampo Announces Fourth Quarter and Full Year 2016 Earnings Call
February 23, 2017 16:02 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its fourth quarter and...
Sucampo Announces Pricing of $260.0 Million 3.25% Convertible Senior Notes due 2021
December 21, 2016 02:00 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), a global biopharmaceutical company, today announced the December 20, 2016 pricing of $260.0 million...
Sucampo Announces Proposed Convertible Senior Note Offering
December 19, 2016 16:01 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), a global biopharmaceutical company, today announced its intention to offer, subject to market and other...
Sucampo Reports Third Quarter 2016 Financial Results
November 09, 2016 06:30 ET
|
Sucampo Pharmaceuticals Inc
Results Driven by 73% Growth in Revenue GAAP EPS Growth of 12%; Adjusted EPS Growth of 58% Company Raises 2016 Guidance and Provides Preliminary 2017 Guidance Announces Settlement with Dr....
Sucampo Reports Strong Results for First Quarter of 2016
May 04, 2016 06:30 ET
|
Sucampo Pharmaceuticals Inc
Results Driven by 60% Growth in Revenue Company Reiterates 2016 Guidance Company to Host Conference Call Today at 8:30 a.m. EDT ROCKVILLE, Md., May 04, 2016 (GLOBE NEWSWIRE) -- Sucampo...
Sucampo Reports Top-Line Data from Phase 2a Study of Cobiprostone in Patients with PPI-Refractory Non-Erosive Reflux Disease (NERD) and Symptomatic Gastroesophageal Reflux Disease (sGERD)
April 19, 2016 07:00 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., April 19, 2016 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced top-line data from a Phase 2a study of...
Sucampo Announces Results of Tender Offer for R-Tech Ueno
October 14, 2015 07:30 ET
|
Sucampo Pharmaceuticals Inc
Tender Achieves Threshold and Tender Offer Period Concludes
Acquisition Expected to Close This Quarter
BETHESDA, Md., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo)...